Arabic Arabic English English French French German German
dark

NLS Pharmaceutics Announces New Study Data Confirming Mazindol’s Unique Orexin Pathway Activation for Treating Narcolepsy

 NLS Pharmaceutics Ltd. announces new study data which support the mechanism of action for mazindol, the active compound in the Company’s lead product candidate to treat narcolepsy, Quilience®. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Agilex Biolabs’ Toxicology Tapped for SARS-CoV-2 Vaccine Research

Next Post

InnoCare Announces Approval of Clinical Trial of TYK2 Inhibitor ICP-332 in China

Related Posts
Total
0
Share